Close Menu

Sequenta

The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.

Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.

Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.

Researchers are demonstrating that sequencing the immune repertoire can offer valuable insight into blood cancers, treatment response, and the likelihood of relapse.

Sequenta and Illumina have struck an agreement to commercialize an in vitro diagnostic kit based on Sequenta's minimal residual disease detection and quantification technology.

NEW YORK (GenomeWeb) – Sequenta said this week that biopharmaceutical firm Celgene and others have made an equity investment into the company.

The University of Massachusetts has been awarded

Korea Institute of Science and Technology has been awarded

This article has been updated with additional details about the ClonoSIGHT test and to clarify that Sequenta is in discussions with the FDA to transition the diagnostic from a lab test to a kit.

Foundation Medicine has launched FoundationOne Heme, a next-generation sequencing-based test that looks for genomic alterations in 405 genes related to hematological cancers. The test also incorporates RNA sequencing of 265 genes to look for gene fusions.

Pages

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.